# URO-1, Inc.

> URO-1, Inc. is a Greensboro, North Carolina medical device company modernizing the prostate biopsy, a procedure its founder describes as largely unchanged in decades. Founded in 2017 by prostate cancer survivor and serial MedTech entrepreneur Ted Belleza, URO-1 makes the FDA-cleared SUREcore biopsy needle and coreCARE tissue transfer system, a paired platform built to collect larger, more intact tissue cores and preserve their integrity on the way to pathology. The company reports its needle hit 92% targeting accuracy in MRI-ultrasound fusion biopsies versus 36% for conventional needles, and began commercial launch in January 2025 following an $8 million Series A.

- **Founded:** 2017
- **Headquarters:** Greensboro, North Carolina, United States
- **Founders:** Ted Belleza (Founder, President & CEO)
- **Team size:** ~10 employees
- **Products:** SUREcore Biopsy Needle, coreCARE Tissue Transfer System, SUREcore Plus
- **Notable:** FDA clearance for both the SUREcore needle and the coreCARE specimen retrieval kit, 92% targeting accuracy in MRI-ultrasound fusion biopsies vs 36% for conventional needles, 72% of SUREcore/coreCARE samples intact vs 40% for standard of care; 60% straight vs 41%

## Products & services

- **SUREcore Biopsy Needle** — A single-use 18-gauge biopsy needle for prostate and soft tissue biopsies, designed to collect larger, higher-quality tissue cores with minimal deflection and fragmentation. FDA-cleared.
- **coreCARE Tissue Transfer System** — A specimen retrieval and transfer platform that preserves biopsy core integrity using a simplified 'touch and go' method, reducing handling and fragmentation before pathology. FDA-cleared.
- **SUREcore Plus** — An extended prostate biopsy instrument within URO-1's transrectal (TRUS) and transperineal (TPBP) product portfolio.

## Achievements

- FDA clearance for both the SUREcore needle and the coreCARE specimen retrieval kit
- 92% targeting accuracy in MRI-ultrasound fusion biopsies vs 36% for conventional needles
- 72% of SUREcore/coreCARE samples intact vs 40% for standard of care; 60% straight vs 41%
- Completed $8M Series A financing led by Acorn Campus of Taiwan (2024)
- Began commercial launch of its prostate biopsy platform in January 2025
- Built a 300-square-foot ISO-certified cleanroom in Greensboro for in-house manufacturing
- Founding team holds 76+ combined patents
- Presented study results at the American Urological Association (AUA) national meetings

## Latest updates

- **2025-05** — Reached a milestone in soft tissue biopsies for prostate cancer detection; featured in a two-part UROTODAY article and presented SUREcore results at AUA 2025.
- **2025-01** — Began commercialization of its prostate cancer biopsy system.
- **2024-03** — Completed $8M Series A financing led by Acorn Campus of Taiwan.

## Links

- Website: https://uro1medical.com
- LinkedIn: https://www.linkedin.com/company/uro-1-inc

---

Profile page: https://yespress.io/uro-1-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-10